Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ocuphire Pharma
Biotech
Processa hands cancer drug back to Opus over time, cost involved
The portfolio streamlining is meant to help Processa focus on another oncology asset, a modified precursor of approved chemotherapy 5-fluorouracil.
Darren Incorvaia
Jul 1, 2025 11:12am
Ocuphire to transform into gene therapy biotech via Opus buyout
Oct 23, 2024 5:31am
Exscientia fires CEO—Chutes & Ladders
Feb 16, 2024 9:30am
Longtime BioMarin CEO hands off baton—Chutes & Ladders
Nov 3, 2023 9:30am
Ocuphire's diabetic eye drug misses phase 2 primary endpoint
Jan 26, 2023 8:32am
